ArraySlide 24-4 chamber to hold 4 slides with 24 compartments per slide. For incubation with various samples in parallel.
ArraySlide 24-4 chamber, including lower carrier tray, upper structure plate, and gasket (patent pending) to hold 4 slides for automated incubation. In combination with PepStar peptide microarrays printed in multiwell format, 21 wells per peptide microarray slide can be incubated in parallel. Application(s): B-cell immunity, Protein-protein-interaction Condition(s)/Topic(s): Standard Delivery Time: 2-5 days
JPT's Array Slide Chamber ArraySlide chamber, including lower carrier tray, upper structure plate, and gasket to hold 4 slides for incubation. In combination with PepStar™ Peptide Microarrays that are printed in multiwell format, 21 samples per peptide microarray slide can be incubated in parallel. The ArraySlide chamber sections peptide microarrays into individual surfaces for multiple simultaneous screening analysis studies. Please contact us for details on peptide microarrays printed in multiwell format!
Benefits of Array Slide Chamber - Easy loading by multi-channel pipettes or automated robots - Utilizes leak free compression fit gasket - No contaminating adhesives
References for ArraySlide 24-4 chamber
Application Notes A Modular Approach for Epitope Discovery and High-Resolution Profiling of Humoral Immune Responses Pawlowski et al. (2013) Full text Multiple Sclerosis and Epstein Barr Virus Infection. An Epitope Mapping Study Reimer et al. (2014) Full text The Challenge of Antigen Sequence Diversity:Solutions with ULTRA Peptide Libraries Pawlowski et al. (2015) Full text Rapid Mimotope Optimization for Pharmacokinetic Analysis of the Novel Therapeutic antibody IMAB362 Daneschar et al. (2014) Full text
Testimonials for JPT's Peptide Microarrays "Over the past five years my research team has been active in the development of species-specific peptide arrays. Our ability to advance this technology into new research areas has been dependent on working with the highest quality of arrays. In this regard, JPT's commitment to excellence has been a critical foundation for the success of our research program. I have been consistently impressed with their customer service, technical expertise and professionalism. When it comes to peptide work there are no other options for our group, JPT is the best." Scott Napper, PhD, Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Canada
"The RV 144 HIV trial is considered as one of first successful HIV vaccine trials. It has become clear that the V2 loop of gp120 is an important site for immunogenicity and protection from HIV infection. The use of JPT's PepStar™ microarray technology has been very useful for the correlation of the clincial outcome with humoral immune responses. As have the cyclic peptides been from JPT to validate these findings!." Jeff Currier, PhD, Walter Reed Army Institute, Rockville, Maryland, USA
"We study modulation of dopaminergic neurotransmisson by TAAR1 and D2R. The functional interaction of the two receptors in the brain supports TAAR1 as a target for the treatment of psychiatric disorders such as schizophrenia or bipolar disorder. To map the epitopes of our newly generated specific anti-rat TAAR1 antibodies we used JPT's PepStarTM peptide microarrays. The peptide microarrays greatly contributed to our successful and recently published study. We were very satisified with the exceptional product and service delivered by JPT Peptide Technologies as well as their scientific Customer Support which was always at our disposal." Stefan Obermüller, F.Hoffmann - La Roche Ltd., Roche Pharma Research and Early Development, Basel, Switzerland